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Abstract
When skeletal muscles are activated and mechanically shortened, the force that is produced by the muscle fibers decreases
in two phases, marked by two changes in slope (P1 and P2) that happen at specific lengths (L1 and L2). We tested the
hypothesis that these force transients are determined by the amount of myosin cross-bridges attached to actin and by
changes in cross-bridge strain due to a changing fraction of cross-bridges in the pre-power-stroke state. Three separate
experiments were performed, using skinned muscle fibers that were isolated and subsequently (i) activated at different Ca
2+
concentrations (pCa
2+ 4.5, 5.0, 5.5, 6.0) (n=13), (ii) activated in the presence of blebbistatin (n=16), and (iii) activated in the
presence of blebbistatin at varying velocities (n=5). In all experiments, a ramp shortening was imposed (amplitude 10%Lo,
velocity 1 LoNsarcomere length (SL)Ns
21), from an initial SL of 2.5 mm (except by the third group, in which velocities ranged
from 0.125 to 2.0 LoNs
21). The values of P1,P 2,L 1, and L2 did not change with Ca
2+ concentrations. Blebbistatin decreased P1,
and it did not alter P2,L 1, and L2. We developed a mathematical cross-bridge model comprising a load-dependent power-
stroke transition and a pre-power-stroke cross-bridge state. The P1 and P2 critical points as well as the critical lengths L1 and
L2 were explained qualitatively by the model, and the effects of blebbistatin inhibition on P1 were also predicted.
Furthermore, the results of the model suggest that the mechanism by which blebbistatin inhibits force is by interfering with
the closing of the myosin upper binding cleft, biasing cross-bridges into a pre-power-stroke state.
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Introduction
A long-standing scientific challenge resides in the explanation
of how characteristics of the molecular actin-myosin interaction
give rise to macroscopically observed phenomena in striated
muscles, and how conditions imposed on macroscopic scales
affect actin-myosin kinetics. In early experiments to connect
macroscopic muscle mechanics to load-dependent cross-bridge
kinetics, step shortenings were imposed to fully activated fibers
isolated from amphibian muscles [1]. The force transients could
be described in four phases: 1) during the fast shortening step,
there was a force decrease proportional to the shortening
amplitude, 2) during the next 3–5 ms there was a rapid force
recovery, 3) during the next 10–50 ms there was an extreme
reduction of force recovery, and 4) during the remainder of
response, there was an asymptotic recovery towards maximum
isometric force. At the end of phase 1, a maximal drop in force
(T1) was observed and the beginning of phase 2 indicated a
transition into an increase of force. A following inflection or even
a low peak in the force time course at force (T2) indicated the
transition into phase 3 [1].
Length ramps performed at constant velocities are now
commonly used for studying the molecular mechanisms of muscle
contraction [1–5], and show force responses that are qualitatively
similar to early studies that used step shortening: 1) the force
decreases in proportion to shortening, 2) the force decrease
becomes less rapid, 3) the force decrease becomes even slower, 4)
and the force shows an asymptotic approach to a lowered but
constant steady state. Some of these studies show a transition in the
force trace from phase 1 to phase 2 (hereafter called critical point
P1) that occurs at a critical sarcomere length (L1), and a transition
in the force trace from phase 2 to phase 3 (hereafter called critical
point P2), that occurs at a critical sarcomere length (L2). While
phase 1 in force traces is commonly associated with a purely elastic
response, the behaviour during phase 2 is attributed to a
repartitioning of cross-bridges from the pre to the post-power
stroke state, due to an acceleration of the power-stroke step under
conditions of lowered mechanical load on myosin cycling [1,3,5,6].
In this study, we reinvestigated the mechanisms responsible for
the force transients during a shortening ramp. We examined fibers
at different levels of Ca
2+ activation, and fibers treated with the
highly specific myosin inhibitor blebbistatin, which biases cross-
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e29356bridges into a pre-power-stroke state [7,8]. Different Ca
2+
concentrations allowed us to examine the influence of the number
of strongly-bound cross-bridges on the force transients during
shortening, while blebbistatin allowed us to investigate the effects of
cross-bridge partitioning into pre and post-power-stroke states
before ramp shortening. While changes in Ca
2+ concentration did
not significantly alter the P1 andtheP2 transitionsduring shortening,
blebbistatin decreased P1 significantly during shortening.
We developed a mathematical cross-bridge model with a load-
dependent power-stroke transition between pre and post-power-
stroke cross-bridge states, which was based on general protein
motor kinetics formalisms [9] and single myosin experiments [10].
Three cross-bridge kinetic states were derived in accordance with
well-defined biochemical pathways [9,11,12] and compatible with
current structural models of myosin [13]. Similar to what other
models investigating ramp stretches have suggested [6,14–17], pre-
power-stroke cross-bridges were found to be a major determinant
of the force transients during shortening. The model explained
qualitatively the force transients (P1 and P2) and the lengths at
which they happen (L1 and L2, respectively) observed in our
experiments using different shortening velocities. It also predicted
the effects of blebbistatin inhibition on P1, further indicating that
the mechanism by which blebbistatin inhibits active force
generation is by preventing the closing of the myosin binding
cleft, effectively biasing cross-bridges into a pre-power-stroke state.
Methods
Muscle fiber preparation
Small muscle bundles of the New Zealand White rabbit psoas
were dissected, tied to wood sticks, and chemically permeabilized
following standard procedures [16,18]. The muscles were
incubated in rigor solution (pH=7.0) for approximately 4 hours,
after which they were transferred to a rigor:glycerol (50:50)
solution for 15 hours. The samples were placed in a new
rigor:glycerol (50:50) solution with the addition of a mixture of
protease inhibitors (Roche Diagnostics, USA) and stored in a
freezer (220uC) for at least seven days. On the day of the
experiment, a muscle sample was transferred to a fresh rigor
solution and stored in the fridge for one hour before use. A small
section of the sample was extracted (,4 mm in length), and single
fibers were dissected in a relaxing solution (pH=7.0). The fibers
were fixed at their ends with T-shaped clips made of aluminum
foil, and were transferred to a temperature controlled experimen-
tal chamber to be attached between a force transducer (Model
400A, Aurora Scientific, Toronto, Canada) and a length controller
(Model 312B, Aurora Scientific, Toronto, Canada). The protocol
was approved by the McGill University Animal Care Committee
(protocol #5227, valid 2006–2016) and complied with the
guidelines of the Canadian Council on Animal Care.
Solutions
The rigor solution (pH 7.0) was composed of (in mM): 50 Tris,
100 NaCl, 2 KCl, 2 MgCl2, and 10 EGTA. The relaxing solution
(pH 7.0) used for muscle dissection was composed of (in mM): 100
KCl, 2 EGTA, 20 imidazole, 4 ATP and 7 MgCl2. The solutions
with pCa
2+ of 4.5, 5.0, 5.5 and 6.0 (pH 7.0) were composed of (in
mM): 20 imidazole, 14.5 creatine phosphate, 7 EGTA, 4 MgATP,
1 free Mg
2+. These solutions had free Ca
2+ ranging from 1 nM
(pCa
2+ 9.0 relaxing) to 32 mM (pCa
2+ 4.5 maximum activation),
and KCl to adjust the ionic strength to 180 mM. A pre-activation
solution (pH 7.0, pCa
2+ 9.0) was used before activating the fibers,
composed of (in mM): 68 KCl, 0.5 EGTA, 20 Imidazole, 14.5
PCr, 4.83 ATP, 0.00137 CaCl2, 5.41 MgCl2 and 6.5 HDTA
(pH 7.0, pCa
2+ 9.0). The final concentrations of each metal-ligand
complex were calculated using a computer program [19] which
takes into account the reaction between the buffers when forming
chemical complexes to calculate the final free ionic concentrations.
The solutions containing blebbistatin were prepared according
to the following procedures. 1 mL of blebbistatin (Sigma, USA)
prepared at 20 mM, previously dissolved in dimethylformamide
(DMF), was diluted in 4 mL of activating (pCa
2+ 4.5) or relaxing
(pCa
2+ 9.0) solutions to reach a final concentration of 5 mM. Care
was taken to limit blebbistatin exposure to light, as it loses its
effectiveness in wavelengths between 365 nm and 490 nm [20]. A
red filter (650 nm) placed on the light source of the microscope
was used to avoid exposure when the use of light was necessary
during the experiments. Solutions were prepared with both the
active and the inactive (+/+) isomers of blebbistatin, which was
used as a negative control.
Experimental protocol
After the fibers were set in the experimental chamber, the
average sarcomere length (SL) was calculated in relaxing solution
using a high-speed video system (HVSL, Aurora Scientific 901A,
Toronto, Canada). Images from a selected region of the fibers
were collected at 1000–1500 framesNsec
21, and the SL was
calculated by fast fourier transform (FFT) analysis based on the
striation spacing produced by dark and light bands of myosin and
actin, respectively. The fiber diameter and length were measured
using a CCD camera (Go-3, QImaging, USA; pixel size:
3.2 mm63.2 mm), and the cross-sectional area was estimated
assuming circular symmetry.
Three separate sets of experiments were performed during this
study, using (i) fibers activated at different Ca
2+ concentrations and
shortened at 1 LoNSLNs
21 (n=13), (ii) fibers activated in the
presence or absence of blebbistatin and shortened at 1 LoNSLNs
21
(n=16), and (iii) fibers activated in pCa
2+ 4.5 and pCa
2+ 6.0 in the
presence of blebbistatin, shortened at varying velocities ranging
from 0.125 LoNSLNs
21 to 2.0 LoNSLNs
21 (n=5). All experiments
were performed at 5uC.
At the beginning of the experiments, the initial SL was adjusted
to 2.5 mm (optimal length, Lo) before activation. (i) For the
experiments with different Ca
2+ concentrations, fibers were
activated at pCa
2+ of 4.5, 5.0, 5.5 and 6.0 (random order). When
force was fully developed in each pCa
2+, a ramp shortening of
10%Lo was applied at a constant velocity of 1 LoNSLNs
21. (ii) For
the experiments with blebbistatin, the fibers were divided in two
sub-groups, treated with either an active form of blebbistatin
(n=12) or an inactive (control) form of blebbistatin (+/+) (n=4).
The fibers were first activated at a pCa
2+ of 4.5 and shortened by
10%Lo, at a velocity of 1 LoNSLNs
21; this trial provided the control
value for these experiments. Following, the fibers were incubated
in relaxing solution (pCa
2+=9.0) containing blebbistatin. After the
incubation period in relaxing solution, the fibers were immersed in
activating solution (pCa
2+=4.5) containing blebbistatin (5 mM).
After full force development, a shortening of 10%Lo at 1 LoNs
21
was applied to the fibers. (iii) For the experiments with different
velocities of shortening (n=12), fibers were activated at pCa
2+ of
4.5 or 6.0 (random order) and then immersed into relaxing (pCa
2+
9.0) and activating (pCa
2+ 4.5) solutions containing blebbistatin
(5 mM), as previously described. When force was fully developed,
ramp shortenings of 10%Lo were applied at velocities of 0.125,
0.25, 0.5, 1.0, or 2.0 LoNs
21 (random order).
In all experiments, control contractions (pCa
2+ of 4.5) were
elicited throughout the experiments; when isometric forces
decreased by .10% from the maximal force produced at the
beginning of the experiment or when the striation pattern
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was ended and data from this fiber was discarded from future
analysis.
Data analysis
The changes in slope of force observed during shortening were
detected using a two-segment piecewise regression, in which the
force trace can be fitted by two linear regression functions:
y1=a 1+b1xi (restriction: xi#x0), and y2=a 2+b2xi (restriction: xi.x0),
where (x0,y0) represents the coordinates of the critical transition (Lc
and Pc measured in this study), a1 and a2 represent the intercepts of
the two regression lines, and b1 and b2 are the slopes of the two
regression lines. At the first iteration, the observations x1,x 2,…x 5
are included to estimate the parameters of the first regression line.
The remaining observations x6,…x n are used to fit the second
regression line. At the next iteration, the observations x1,…x 6 are
included to estimate the parameters of the first regression line, and
the remaining observations x7,…x n are used to fit the second
regression line. The same procedure is performed in all iterations.
The residual sum of squares (RSS) is based on the sum of the
squares of each regression line:
RSS~
X
xiƒx0
yi{(a1zb1|xi) ½ 
2z
X
xiwx0
yi{(a2zb2|xi) ½ 
2
The RSS is used to determine the optimal values of a1, a2, b1, b2,
and x0 – the values associated with the minimal RSS are
considered optimal [21]. The regression results were accepted
when they presented a correlation coefficient (r
2).0.99, and data
points fitted inside a 95% confidence interval (CI) of the regression
lines, similar to procedures used previously in our laboratory [16].
In cases in which these criteria were not fulfilled, we used two
approaches to detect the breakpoints, two single regression lines
were fitted into the two slopes, which were extrapolated visually to
detect the breakpoint [5,16,22]. Regression lines were accepted
when the correlation coefficient (r
2) were .0.99 and data points
fitted inside a 95% confidence interval. The force produced during
the first and second changes in slope were calculated at the
transition points (P1 and P2, respectively). L1 and L2 were
determined as the length change amplitudes necessary to achieve
the P1 and P2 transitions, measured from the beginning of
shortening. In a few experiments, the signal from the striation
pattern arising from the fibers became weak during shortening; in
this case, the L1 and L2 were calculated by extrapolating the
percentage of change in fiber length (measured during the
experiments) based on the SL measured just before shortening.
Both methods provided similar results, as confirmed in experi-
ments in which SL was measured.
The values of P1,P 2,L 1, and L2 were compared among
different pCa
2+ or blebbistatin conditions using a one-way
ANOVA for repeated measures. When significant changes were
observed, post-hoc analyses were performed with Newman-Keuls
tests. For the third group of experiments a two-way ANOVA (3
conditions65 velocities) for repeated measures were used to
compare the P1,P 2,L 1 and L2. When significant interactions or
main effects were found, post-hoc comparisons using Newman-
Keuls adjustment for multiple comparisons were performed to
locate significant differences. The significance level for all
statistical tests was set at P,0.05.
Model development
We developed a cross-bridge model consisting of two major
elements: (1) an active molecular contractile element, consisting
of cross-bridges capable of contraction and (2) a passive element
with linear elasticity, which is placed between the active
contractile element and the external apparatus which controls
fiber length.
Cross-bridge kinetics
We assumed that the number of cross-bridges in the fiber is high
enough to support a treatment of cross-bridge populations, instead
of monitoring single cross-bridges. According to a simple Attach
— Power-stroke — Detach scheme (Figures 1 and S1), we
monitored three general populations of cross-bridges: x1 – pre-
power-stroke, x2 – post –power-stroke, x3 – non-bound (Figure 1).
Cross-bridge transition between these populations occur at rates
kij; i=1,2,3 is the source population where the cross-bridge comes
from, and j=1,2,3 is the sink population which the cross-bridge
transits into. Based on these transition rates, we can describe the
cross-bridge population dynamics in a set of two ordinary
differential equations (ODEs):
dx1=dt~{(k12zk13)x1zk21x2zk31x3,
dx2=dt~{(k23zk21)x2zk12x1zk32x3,
x3~1{x1{x2,
where xi represent the fraction of the total cross-bridges that can be
found in the kinetic state xi. We used the normalization
x1+x2+x3=1to reduce the system from three ODEs to two ODEs,
because x3 can be calculated from x1 and x2 as described in above
expressions. All transition rates except those containing the power-
Figure 1. Overview of mathematical model. The mathematical
model comprises a load-sensitive active cross-bridge component
adjusting the molecular contractile apparatus length Lmol, and a passive
element with a linear force response to differences between the
externally set fiber length L and Lmol. A three-state cross-bridge kinetic
cycle with a load-dependent power-stroke transition from the pre to
the post-power-stroke state is assumed.
doi:10.1371/journal.pone.0029356.g001
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containing the power-stroke have an exponential dependence on
load F, which is multiplied by the power-stroke step size Dd and
enters as work into the exponent:
k23,k32,k31,k13~const:
k12!e{FDd=2,k21!eFDd=2:
For exact expressions in terms of ATP, ADP, Pi concentrations,
myosin affinity for actin, and zeroth order transition rates, see
Text S1. Ionic strength, [Ca
2+] and pH are assumed to be
implicitly contained in the effective zeroth order rates for all
transitions.
Measured force
The measured force P is determined by the stretch of the passive
elastic element. This stretch, in turn, is determined by the
difference between L, the overall length of the fiber, and Lmol, the
length of the molecular contractile apparatus multiplied by the
elastic modulus C:
P~  C C(L{Lmol):
The fiber length L is externally set by the operator; we use the
following time course to model a shortening ramp
L(t)~min(0,max(Lmax=(vrampL0),t))vrampL0,
so that the ramp starts at time t=0, the length L(t=0)=0 is set
equal 0 for the maximum isometric contraction point at t=0(see
Figures 2 D, 2E, and 2F). The fiber length L is changed at a
constant velocity vramp up to a total shortening length by Lmax. Note
that in case of shortening vramp, Lmax,0.
Figure 2. Simulated force during ramp shortening protocol with detected critical points. Top row (A, B, C) shows measured force P vs.
time, bottom row (D, E, F) shows fiber length L vs. time. Triangles and circles represent P1 and P2 critical points, respectively. Negative times
correspond to times before start of shortening ramp, fiber activated at time 2150t0 in simulation and held isometrically up to time 0. Grey
background rectangles indicate regions which are displayed at higher time resolution in the next graph to the right. Five traces are simulated with
ramp velocities 0.125L0/t0, 0.25L0/t0, 0.5L0/t0,1 L 0/t0 and 2L0/t0. Simulation parameters are presented in Text S1.
doi:10.1371/journal.pone.0029356.g002
Table 1. Relative force decrease (%) in contractions produced
in the different experimental conditions, when compared to
contractions produced at pCa
2+ 4.5.
Experiment
(i) (ii) (iii)
pCa
2+ 5.0 20615 - -
pCa
2+ 5.5 18617 - -
pCa
2+ 6.0 5965* - 55610*
Blebbistatin - 6066* 7264*
Legend: (i) first set of experiment, with fibers activated at four Ca
2+
concentrations, (ii) second set of experiments, with fibers activated in presence
or absence of blebbistatin, and (iii) third set of experiments, with fibers
activated in pCa
2+ 4.5 (with and without blebbistatin) and pCa
2+ 6.0. The three
sets of experiments correspond to the description given in Methods.
*Significantly different from contractions produced at pCa
2+ 4.5 (p#0.05).
doi:10.1371/journal.pone.0029356.t001
Figure 3. Typical experiment overview – pCa
2+4.5 and 6.0.
Sample records from a typical experiment showing the force produced
by a muscle fiber activated in pCa
2+ 4.5 (upper trace) and pCa
2+ 6.0
(lower trace). Force rises during activation and then stabilizes to achieve
a plateau. During shortening the force decays rapidly. After the
shortening, the forces recover slowly to achieve a new steady-state.
doi:10.1371/journal.pone.0029356.g003
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2+ concentrations. (A) Superimposed contractions showing the force
decrease during shortening while the fiber was activated at different Ca
2+ concentrations (top), with the corresponding length change (bottom). All
forces were normalized by their respective isometric forces (Po) before the ramp shortening. P2 and L2 did not change at increasing Ca
2+
concentrations. (B) Closer view from the initial shortening phase of the experiment with another fiber, showing clearly that P1 and L1 do not change
with different Ca
2+ concentrations. The critical points in this figure were detected with regression analyses; the regression lines are shown in blue
(pCa
2+ 4.5) and green (pCa
2+ 5.5) traces.
doi:10.1371/journal.pone.0029356.g004
Figure 5. Mean critical values for different Ca
2+ concentrations. Mean values (6 S.E.M) of P1 and P2 (A), and L1 and L2 (B) in experiments
performed with different Ca
2+ concentrations. Changing the pCa
2+ did not change any of the variables.
doi:10.1371/journal.pone.0029356.g005
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The active contractile element and the passive elastic element
interact in two ways:
(1) The force P on the fiber, which develops in the passive elastic
element in response to stretch, is divided by the number of
attached myosin heads, and thereby gives the load F
experienced by a single attached myosin head
F~
P
N(x1zx2)
,
which in turn influences the transition rates of the forward
and reverse power-stroke steps. N is the total number of cross-
bridges in the fiber.
(2) Cross-bridges transitioning through the forward or reverse
power-stroke step decrease or increase Lmol (the length of the
active molecular contractile element), respectively. The change
in Lmol can be calculated by multiplication of the forward flux
through the power-stroke state by the power-stroke step size
d
dt
Lmol~NDd(k21x2{k12x1):
Lmol, together with L, determines the stretch of the passive
elastic element, and thereby the measured fiber force.
Implementation of experimental protocol, measurement
of critical points
To reproduce the experimental ramp shortening protocol in a
simulation of our model, we allowed the fiber to reach a force
Figure 6. Typical experiment overview – pCa
2+4.5 and blebbis-
tatin. Sample records from a typical experiment showing the force
produced by a muscle fiber activated in pCa
2+ 4.5 (upper trace) and
then treated with blebbistatin (lower trace). Force rises during
activation and then stabilizes at a steady-state level. During shortening
the force decreases. After the shortening, the forces recover slowly to
achieve a new steady-state.
doi:10.1371/journal.pone.0029356.g006
Figure 7. Experimental detection of critical points in fibers treated with blebbistatin. (A) Superimposed contractions, showing the force
decay during shortening while the fiber was activated with pCa
2+ 4.5- (solid line), and then treated with blebbistatin (dashed line), with the
corresponding fiber length changes. All forces were normalized by their respective isometric forces (Po) before shortening. P2 and L2 did not change
with blebbistatin. (B) Closer view from the initial shortening phase of the experiment with another fiber, showing that blebbistatin induced a higher
force decrease before P1. It also shows that blebbistatin induced greater P1 amplitude when compared the contraction produced before blebbistatin.
L1 was not changed by blebbistatin. The critical points in this figure were detected with regression analyses, the regression lines are shown in blue
(pCa
2+ 4.5) and red (pCa
2+ 4.5+blebbistatin) traces.
doi:10.1371/journal.pone.0029356.g007
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Dependent on ramp velocity, the time of the ramp shortening was
adjusted in each contraction to reach the same ramp lengths
independent of ramp velocity (see Figures 2D and 2E). We
simulated our model using the MatLab ode15s adaptive time step
size integrator for stiff ODEs (for resulting traces see Figures 2 and
S2). We found regular ODE integrators to be inefficient due to the
rapid changes in force right after beginning of the ramp
shortening. The P1 and P2 transitions were detected based on
the curvature Curv of the force time course L(t).A tP 1, the linear
force decrease transitions into a less steep decrease, Curv at this
‘‘kink’’ has a prominent peak which we used to detect P1;
considering P1 as a transition from a phase with marked shifts in
the cross-bridge populations to a phase of exponential approach to
a new steady state, we detected P2 as a characteristic transition in
log10(Curv) from a curved decay to a linear decay (exponential
decay displays as a linear decay on a log-scale) (see Figures 2 and
S3).
Results
Experimental results
The isometric forces were altered by Ca
2+ concentration
changes as well as by blebbistatin (Table 1). When contractions
were produced in pCa
2+ 5.0 or 5.5, a not statistically significant
trend towards decreased force was visible, and contractions in
pCa
2+ 6.0 showed a significant decrease in force relative to
contractions produced at pCa
2+ 4.5. When fibers were treated
with blebbistatin, there was a significant force decrease, in
accordance with previous studies that reported a decrease of
,60% when using 5 mM of blebbistatin [7,16,23]. The effects of
blebbistatin are highly dependent on the experimental conditions;
differences of ,20% are observed in studies that use similar
blebbistatin concentrations [7,23]. Note that the inactive isomer of
blebbistatin (+/+) also decreased the force by a small magnitude, a
result that has been reported previously [16,23]. However, during
shortening, we did not find any difference between the inactive
form of blebbistatin and the control experiments, as previously
observed [16]. For reasons of clarity we will therefore report only
the results of experiments using the active form of blebbistatin.
Effects of Ca
2+ concentrations. Figure 3 shows two
contractions (pCa
2+ 4.5 and 6.0) recorded during a typical
experiment performed in this study. In both cases the force rose
quickly during activation to reach different steady-state levels – in
this case the force produced at pCa
2+ 6.0 was 40% of the force
produced at pCa
2+ 4.5. Once full force development was obtained,
the fiber was shortened and the force rapidly decreased to zero.
The force was then redeveloped to reach a new steady state, after
which the fiber was deactivated (deactivation not shown).
We were mostly interested in the transient force changes during
shortening. Figure 4A shows a zoomed image of the shortening
phase during two contractions produced in different pCa
2+. The
force was normalized by the maximum isometric force produced
just before shortening. In this case the values of P2 and L2 were not
different among the different contractions. In Figure 4B we
changed the graph scale to show the P1 force transition, which was
clearly detected. The values of P1 and L1 did not change during
the shortening with different pCa
2+. The results observed in this
experiment were confirmed statistically, and despite the increase in
Po following the increase in Ca
2+ concentrations, none of the
Figure 8. Mean critical values of fibers treated with blebbistatin. Mean values (6 S.E.M.) of P1 and P2 (A), and L1 and L2 (B) in experiments
where fibers were treated with blebbistatin. Blebbistatin changed P1 significantly. None of the other variables were changed. * Significantly different
from all other conditions (P,0.05).
doi:10.1371/journal.pone.0029356.g008
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affected by changes in pCa
2+ (Figure 5). When all pCa
2+ data were
pooled, P1 and P2 were 0.7960.003 and 0.2760.01 times Po,
respectively, and L1 and L2 were 4.6260.16 and 24.176
0.20 nmNHS
21 respectively.
Effects of blebbistatin. Figure 6 shows two contractions
recorded during the same experiment before and after blebbistatin
treatment. Blebbistatin substantially decreased the maximum
isometric force, but the response to shortening was similar to
control experiments: the force decreased quickly to almost zero to
then redevelop towards a new steady-state level. Figure 7 shows a
zoomed image of the shortening phase in an experiment where the
fiber was activated at pCa
2+ 4.5 and treated with blebbistatin (+/
2). The force was normalized by the maximum isometric force.
The values of P2 and L2 were not different before and after
blebbistatin treatment (Figure 7A). However, P1, also detectable
for this condition, decreased significantly after blebbistatin
treatment, while L1 was not changed (Figure 7B). The results
shown in the experiment depicted in Figure 7 were confirmed
statistically (Figure 8). P2 and L2 were not statistically different
from the control group (pCa
2+4.5). The P1 amplitude (absolute
distance between the critical point and Po) was significantly higher
after blebbistatin treatment when compared with the control, as
shown in a higher force decrease, while L1 was not affected by
blebbistatin (Figure 8B).
Effects of shortening velocity. Figures 9A and 9C show
records of contractions in which ramp shortenings at different
(constant) velocities were applied in two fibers activated in pCa
2+
4.5 and treated with blebbistatin, respectively. The P2 amplitude
and L2 were augmented with increasing velocities, as previously
shown [5]. Figures 9B and 9D show a closer view of the force
records from panels A and C respectively in which the P1
Figure 9. Critical points behaviour at different velocities. (A) Force responses (upper traces) to ramp shortenings (lower traces) in a range of
velocities (0.125–2 Lo.s
21) from one set of experiments performed with one fiber activated with a pCa
2+ 4.5. The rate of force decay increased with
shortening velocities. (B) Closer view from the same traces, showing increasing P1 amplitude (upper traces) and L1 (lower traces) with increasing
velocities. (C) and (D) Same as in A and B, now showing traces of another fiber treated with blebbistatin (3 velocities displayed).
doi:10.1371/journal.pone.0029356.g009
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velocity, which was accompanied by an increase in L1. The
amplitudes of P1,P 2,L 1, and L2 increased with velocities, in all
conditions investigated. There was not a difference detected in P2,
L1, and L2 among the three conditions, although the P1 amplitude
increased in fibers treated with blebbistatin. Figure 10 shows the
mean (6 S.E.M) values for P1 activated in pCa
2+ 4.5, 6.0 and after
treatment with blebbistatin. The velocity-P1 curve was shifted
downward in fibers treated with blebbistatin.
Model results
Using our model (for parameter values see Table 1 in Text S1),
the dependence of P1,P 2,L 1, and L2 on ramp velocity observed in
our experiments without blebbistatin could be qualitatively
explained (Figure 11); the critical P1 and P2 decreased and the
critical L1 and L2 increased with increasing ramp velocity. We also
observed the characteristic nonlinear dependencies of the critical
force transitions during the shortening; the monotonous upward
and downward tendencies observed in experiment for P1,P 2,L 1,
and L2 are all accounted for by our model results.
Mechanism of blebbistatin inhibition. The power-stroke
inhibitor blebbistatin is believed to affect the tight binding of
myosin to actin. Its characteristic molecular structure targets the
myosin-actin binding interface, and the closing of the myosin’s
actin-binding cleft is hindered. Conceptually, there are two not
mutually exclusive ways to incorporate this mechanism into cross-
bridge kinetics: (1) as the establishment of inter-protein molecular
bonds is disturbed by the presence of blebbistatin, the binding
energy of the tight-bound post-power-stroke state is reduced, or
(2) as the closing of the actin binding cleft is hindered, the zeroth
order transition rate of the power-stroke is reduced. In terms of
the molecular potential energy profile, these changes correspond
to an increase of the potential energy level of the pre-power-
stroke state, or the increase of the reaction energy barrier of the
transition between the pre and the post-power-stroke state,
respectively (see Figure 12). Intuitively, case (1) would be
expected to lower the effective affinity between actin’s myosin
binding sites and myosin heads. Case (2) would be expected to
slow down the power-stroke transition, but not to change the
effective myosin-actin affinity. Both alterations are in line with
findings from biochemical and structural studies of kinetic
mechanism of blebbistatin [8,24–26]. However, we can show
that in case (2) no reduction in the isometric maximum force Po is
predicted with blebbistatin. In case (1), Po decreases
monotonously with increasing concentration of blebbistatin.
Thus, a decreased binding energy of the strongly bound cross-
bridges as described under (1) is the necessary mechanism of
action and used for the following model predictions of the
blebbistatin effect.
Prediction of critical points with blebbistatin
inhibition. We introduced the kinetic influence of
blebbistatin into our model as a reduction of the binding
energy by DE=0.35kBT. This alteration predicts a prominent
reduction of the P1 and P2 and minimal changes in L1 and L2.
Applying the power-stroke inhibitor blebbistatin in our
experiment caused a significant decrease in P1 force and no
significant changes for P2,L 1, and L2. Thus the predicted and
measured qualitative effects of blebbistatin are the same for P1,L 1
and L2; the case of P2 is unclear. Applying alternatively an
increase in the zeroth order rate constant of the power-stroke by a
factor 1/1.75 predicts similar effects on the critical points (Figure
S4), thus a decrease in the energy of tight binding of myosin to
actin is a necessary mechanism to explain our results, the
reduction of the zeroth order power-stroke transition rate is a
possible one.
Figure 10. Mean critical values at different velocities. Mean (6 S.E.M.) of the P1 values at five different velocities in a fiber activated with pCa
2+
4.5 (dotted line), 6.0 (solid line) and treaded with blebbistatin (solid line with inverted triangles). Blebbistatin changed P1 significantly at all five
velocities. *Significantly different from all other conditions (P,0.05).
doi:10.1371/journal.pone.0029356.g010
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In this study we detected an early force transition during an
imposed shortening of activated muscle fibers (P1), depicted as a
change in slope prior to P2 during shortening [1,2,5]. In our
experiments, when different velocities (0.125 to 2 LoNSLNs
21) were
applied, P1 amplitude (i.e. distance between Po and critical force)
ranged between 20.03 and 20.39 times Po and L1 amplitudes
ranged between 0.5 and 7.0 nmNHS
21; the higher the velocity the
higher P1 and L1 amplitude; in agreement with previous studies
[5]. We also observed values for P2 and L2 that were within the
range observed in previous studies; when a 10%Lo shortening was
performed at velocities ranging from 0.125 to 2 LoNSLNs
21, the
values of P2 and L2 ranged between ,0.65 and 0.20 times Po and
,15 and 27 nmNHS
21.
Experiments with different Ca
2+ concentrations
Despite the velocity dependence of P2, the values did not change
with Ca
2+ concentrations (pCa
2+ 4.5, 5.0, 5.5 and 6.0), suggesting
that P2 values are independent from the number of cross-bridges
attached to actin. Although estimating the number of strongly-
bound cross-bridges in a given moment during contractions is
challenging, there is evidence that the number does not exceed
40% at high Ca
2+ concentrations. One study that experimented
with permeabilized fibers from the rabbit psoas muscle, and used
stiffness measurements, to calculate the relative proportion of
cross-bridges attached to actin, found a value of ,33% of cross-
bridges attached to actin during isometric contractions produced
at saturating Ca
2+ concentration [27]. It is likely that the number
is similar to what we have in our experiments.
To our knowledge, no other studies evaluated the effects of Ca
2+
concentrations on P2 during shortening. If we assume that the
amount of cross-bridges formed before shortening do not change
the strain necessary for their detachment, and the critical forces
(P2) normalized by their isometric forces, as well as their
correspondent critical length (L2), should not change. Previous
studies that evaluated P1 during shortening [5] have suggested that
this early inflexion is born mostly by pre-power-stroke cross-
bridges (newly attached cross-bridges) performing the power-
stroke. Assuming that increasing Ca
2+ concentration alters forces
Figure 11. Blebbistatin effect on ramp shortening critical points in experiment and model simulation. (A) Experimentally measured P1
for different ramp velocities. Solid line: pCa
2+ 4.5 with blebbistatin, dotted and dashed line: pCa
2+ 4.5 and pCa
2+ 6 without blebbistatin, respectively.
(B) P1 detected in simulation for different ramp velocities. Solid line: blebbistatin inhibition modeled by lowering of myosin actin tight binding energy
by DE=0.35kBT. Dashed line: no blebbistatin inhibition. (C, D, E) Experimentally determined L1,P 2,L 2, respectively; same conditions as in (A). (F, G, H)
L1,P 2,L 2 detected in simulated ramp shortening, respectively; same conditions as in (B). For simulation parameters see Text S1.
doi:10.1371/journal.pone.0029356.g011
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without necessarily affecting the distribution of the population of
myosin attached to actin into pre and post-stroke states, it is
expected that P1 would not change with different Ca
2+
concentrations.
Modelling cross-bridge kinetics
The developed model explains qualitatively L1,P 1,L 2, and P2
for different ramp velocities. A parameter change representing the
known kinetic effects of blebbistatin also predicts the experimen-
tally observed L1,P 1, and L2. Furthermore, on the level of
actomyosin interaction, the model is mechanistic and based on
experimental results. Together, these findings imply that impor-
tant aspects of the underlying molecular kinetics are captured in
the model. It therefore seems appropriate to extend our
investigation of the cross-bridge kinetics underlying the ramp
shortening force response using this model.
It has been hypothesized in earlier experimental and model
studies that the P1 critical point is associated with a transition from
a purely elastic phase to a repartitioning of the cross-bridge
populations in response to a decreased load on the bound cross-
bridges. As can be seen in Figure 13, short after the ramp
shortening started, only a minimal change in the cross-bridge
populations was visible. This corresponds to a phase in which only
the passive elastic elements in the muscle fiber are shortened,
which decreases the measured force as well as the load on the
bound cross-bridges. When P1 is reached, the load on bound cross-
bridges is decreased so far as to appreciably increase the power-
stroke forward transition rate. As an effect, the pre-power-stroke
cross-bridges go through the power-stroke fast, and an increasing
percentage of cross-bridges appears in the post-power-stroke and
the non-bound state. This shift in the cross-bridge populations first
increases, and then decreases again till the cross-bridge popula-
tions reach a new steady state for the changed loading conditions.
The behaviour of the cross-bridge populations visible in Figure 13
around the second critical point at P2 suggests an association of P2
with the transition from an increasing to a decreasing shifting
behaviour in the cross-bridge populations, resulting in an
asymptotic approach to a new, lowered steady state tension value.
Mechanism of blebbistatin inhibition
When the fibers were treated with blebbistatin, a decrease in the
maximum isometric force P0 was observed. There was a significant
decrease in P1, but no significant changes in L1,P 2 and L2 after
blebbistatin treatment. Blebbistatin is a myosin inhibitor that
causes both, a reduction in the number of cross-bridges strongly
attached to actin, and a redistribution of cross-bridges towards a
weakly bound state, stabilizing the myosinNADPNPi complex into a
pre-power-stroke state [7,8,24]. Investigation of our model
indicated that a decrease in the binding energy of the myosin-
actin tight binding is a necessary molecular mechanism of
blebbistatin inhibition of active force development, in contrast to
a reduction in the zeroth order rate constant of the power-stroke
transition it can explain the P0 reduction. This is in agreement
with the hypothesized disturbance of the tight binding protein-
protein interface [7,8,24]. Decrease of the strength of tight binding
as well as a reduction of the zeroth order rate constant of the
power-stroke transition were found to explain the observations for
P1,L 1, and L2.
Since we observed that blebbistatin affects some of the
contractile parameters during shortening and varying Ca
2+
concentration had no effect, it is important to discuss the
difference between force inhibition by blebbistatin and by the
Ca
2+-troponin-tropomyosin complex. According to the most
accepted model of force regulation [28], when Ca
2+ binds to the
troponin C (TnC), it causes the displacement of tropomyosin,
allowing cross-bridge attachment to actin and forming a weakly
bound myosin–actin–ATP complex. ATP is then hydrolysed and
phosphate is released, forming a strongly bound myosin–actin–
ADP complex. The strongly bound complex causes conforma-
tional changes in the thin filament, increasing the probability of
new cross-bridges to attach to actin. Therefore, the troponin-
tropomyosin complex regulates force production mostly by not
allowing myosin-cross bridges to attach to actin, while blebbistatin
decreases the formation of the strong-bound step, after the
formation of the myosinNADPNPi complex.
Figure 12. Molecular mechanism of blebbistatin inhibition
visualized in the cross-bridge cycle potential profile. We display
here the two suggested mechanisms of blebbistatin inhibition, each
with its specific effect on the potential profile. The solid curve
represents the free energy profile without blebbistatin inhibition; the
dashed curve represents the qualitative change from blebbistatin
addition. A progression through states 1, 2, 3 and finally back to 1 (from
left to right) corresponds to completion of one actomyosin cross-bridge
cycle by sequential transition through the kinetic states. The elevations
between the kinetic states correspond to reaction barriers; these
transitions require activation energy, so a higher barrier lowers the
transition rates across this barrier. (A) Reduction of binding energy of
myosin tight-binding to actin, manifesting itself as an increase of the
post-power-stroke energy level. Our model analysis indicates that this is
a necessary mechanism of blebbistatin inhibition. (B) Reduction of the
power-stroke zeroth order rate constant. Our model analysis indicates
that this is a possible but not a necessary mechanism of blebbistatin
inhibition. Potential profiles are only qualitative illustrations and not
drawn to scale.
doi:10.1371/journal.pone.0029356.g012
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Our model predicts surprisingly low occupancies of the post-
power-stroke state at maximal isometric contraction (see Figure 4
and a more general derivation in Text S1). While maintenance of
maximal isometric force by mostly pre-power-stroke cross-bridges
is not necessarily wrong, the large presence of pre-power-stroke
cross-bridges disagrees with X-ray diffraction studies showing
,40% of cross-bridges in the (stereospecifically bound) post-
power-stroke state during isometric contraction at physiological
temperatures [29]. However, when we include the stress-sensitivity
of ADP release hypothesized for skeletal muscle [30], a non-
vanishing percentage of cross-bridges in the post-power-stroke
state for maximal isometric force becomes possible (see Text S1).
Therefore, the strain-sensitivity of the ADP release might play a
greater role in ramp force responses than appreciated so far. From
the first comprehensive models of muscle molecular mechano-
chemistry [12] to more recent modeling studies [31], a strain-
sensitive ADP release has been assumed, thus it should be an
interesting future direction for more realistic models of skeletal
muscle cross-bridge kinetics in ramp shortening and lengthening
experiments.
Supporting Information
Figure S1 Cross-bridge kinetic scheme used in the
general model. Three kinetic states are assumed: (1) a pre-
power-stroke state, (2) a post-power-stroke state, and (3) a non-
bound state, in which myosin is not attached to actin. The
transition ratefunctions kij displayed with the arrows between the
kinetic states characterize the dynamic behavior of the cross-
bridge population. Solid arrows indicate transitions, which are
part of the regular cross-bridge cycle. The dashed line is a
transition stemming from reverse stretch of pre-power-stroke
myosin, which detaches from actin without completing the regular
cross-bridge cycle. The transition associated with rate k13 contains
contributions from the regular cross-bridge cycle as well as
‘‘ripping’’, i.e. forced detachment of myosin cross-bridges from
stretch on the fiber. In the main paper, we use a reduction of this
model, where all parameters related to this forced cross-bridge
‘‘ripping’’ are set equal 0.
(EPS)
Figure S2 Ramp shortening and lengthening model
traces. The characteristic P1 and P2 transitions for ramp
shortening (traces with force decrease during ramp) and
lengthening (traces with force increase during ramp) become
visible from simulation of the general model. For features observed
in experiment see Pinniger et al. and Roots et al. [5,7 in Text S1].
(A) Force vs. time for the complete experimental protocol
including isometric contraction at negative times and a ramp
stretch beginning with time t=0and ending when maximal ramp
length is reached. (B) Zoom into (A) to make visible features of the
overall force response including the P2 features of lengthening and
shortening and the P1 characteristic indentation of the lengthening
force response. (C) Zoom of A) to make visible the early force
response including the P1 characteristic force drop right after
beginning of a ramp shortening. Ramp velocities Vramp=22L0
M,
21L0
M,1 L 0
M,2 L 0
M; simulation parameters given in table in Text
S1, general model.
(EPS)
Figure S3 Detection of critical points from simulated
force responses to ramp shortening. In all graphs heavy
lines represent a simulation for Vramp=2.0L0, the regular lines are
for Vramp=1, 0.5, 0.25, 0.125, in respective order away from the
heavy line. (A) L(t) (solid black) and Lmol(t) (dashed red) in units of
L0 vs. time in units of t0. After starting the ramp L decreases, and in
effect Lmol becomes more similar to L, which effects a force
decrease. (B) Force response to ramp shortening. Circles indicate
Figure 13. Simulated cross-bridge dynamics during ramp shortening protocol with ramp velocity 2L0/t0. A logarithmic time scale was
used for all positive times; time 0 indicates start of ramp shortening, negative times indicate isometric contraction phase before ramp shortening. (A,
B) Force production, triangle and circle represent critical points P1 and P2, respectively. (C, D) Percentage of actively cycling cross-bridges in the
different kinetic states. Note logarithmic scaling of vertical axis. (E, F) Effective flux of cross-bridges from pre- to post-power-stroke-state and from
post-power-stroke state to detached state. The effective flux is the rate at which cross-bridges go from a state xi to a state xj minus the rate at which
cross-bridges go from xj to xi. Note logarithmic scaling of vertical axis. See also Discussion section and Text S1; simulation parameters are included in
Text S1.
doi:10.1371/journal.pone.0029356.g013
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PLoS ONE | www.plosone.org 12 January 2012 | Volume 7 | Issue 1 | e29356the P1 transition, triangles the P2 transition. (C) Percentage of
cross-bridges in pre-power-stroke (solid black), post-power-stroke
(dotted blue) and Non-bound (dashed red) State. (D) log10 of the
curvature Curv of the force response. Circles indicate the detection
points of P1 at the first curvature maximum. (E) First derivative
with respect to time of log10(Curv). (F) Second derivative with
respect to time of log10(Curv). Triangles indicate the detection
points of P2 at the first maximum with a negative value in the first
time derivative.
(EPS)
Figure S4 Blebbistatin effect on ramp shortening crit-
ical points in experiment and model simulation assum-
ing reduction of the power-stroke zeroth order rate
constant. (A) Experimentally measured P1 for different ramp
velocities. Solid line: pCa4.5 with blebbistatin, dotted and dashed
line: pCa4.5 and pCa6 without blebbistatin, respectively. (B) P1
detected in simulation for different ramp velocities. Solid line:
blebbistation inhibition modeled by reduction of the zeroth order
power-stroke-rate constant k0’=k 0/1.75. Dashed line: no blebbis-
tation inhibition. (C, D, E) Experimentally determined L1, P2, L2,
respectively; same conditions as in (A). (F, G, H) L1, P2, L2
detected in simulated ramp shortening, respectively; same
conditions as in (B).
(EPS)
Text S1 Cross-bridge model development and analysis.
(PDF)
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